Cuvitru

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire

Conditions

Primary Immunodeficiency Diseases (PID)

Phase 4

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

CompletedNCT03116347

Baxalta now part of ShirePrimary Immunodeficiency Diseases (PID)

Start: 2017-05-30End: 2021-01-15Updated: 2023-01-11

Unknown Phase

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

CompletedNCT03716700

Baxalta now part of ShirePrimary Immunodeficiency Diseases (PID)

Start: 2018-09-24End: 2020-07-23Updated: 2021-03-05

Related Papers

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Allergy Asthma and Clinical Immunology2024-09-171 citations

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.

2022-08-0710 citations